VIRGINIA RETIREMENT SYSTEMS ET Al Acquires Shares of 6,600 TransMedics Group, Inc. $TMDX

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 6,600 shares of the company’s stock, valued at approximately $741,000.

Several other large investors have also modified their holdings of the company. Opal Wealth Advisors LLC purchased a new stake in TransMedics Group in the 2nd quarter valued at $26,000. Sound Income Strategies LLC purchased a new stake in shares of TransMedics Group in the second quarter valued at about $48,000. Elevation Point Wealth Partners LLC acquired a new stake in TransMedics Group during the 2nd quarter worth approximately $48,000. EverSource Wealth Advisors LLC increased its holdings in shares of TransMedics Group by 72.0% in the second quarter. EverSource Wealth Advisors LLC now owns 485 shares of the company’s stock valued at $65,000 after purchasing an additional 203 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in shares of TransMedics Group by 24.5% in the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock valued at $72,000 after purchasing an additional 108 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Up 0.9%

TMDX opened at $122.69 on Monday. The business’s fifty day moving average is $128.91 and its two-hundred day moving average is $121.93. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The company has a market cap of $4.19 billion, a price-to-earnings ratio of 49.67 and a beta of 2.03. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. The business had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The business’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter last year, the business posted $0.12 earnings per share. Analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Morgan Stanley lifted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Sunday, December 28th. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Needham & Company LLC upped their price objective on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Finally, Evercore ISI initiated coverage on TransMedics Group in a research report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus price target of $144.25.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the transaction, the insider owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. This trade represents a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the completion of the transaction, the director directly owned 2,866 shares of the company’s stock, valued at $373,869.70. The trade was a 59.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 13,062 shares of company stock valued at $1,797,634. Company insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.